Brief: Lipigon And 5Prime Sciences To Optimize Coming Clinical Trials

Lipigon Pharmaceuticals AB

04/11/2021 09:27

Nov 4 (Reuters) - Lipigon Pharmaceuticals AB  LPGO.ST :
    * LIPIGON AND 5PRIME SCIENCES ENTER PARTNERSHIP TO OPTIMIZE
COMING
CLINICAL TRIALS
    * TODAY ANNOUNCED A PARTNERSHIP WITH 5PRIME SCIENCES
("5PRIME") TO
ACCELERATE DEVELOPMENT OF LIPID-LOWERING DRUG CANDIDATE
LIPISENSE FOR UPCOMING CLINICAL TRIALS
    * 5PRIME WILL, AMONG OTHER THINGS, INVESTIGATE WHICH PATIENT
GROUPS WILL BENEFIT MOST FROM ANGPTL4 INHIBITION
    * BY PARTNERING, 5PRIME WILL BECOME LIPIGON'S IN-HOUSE HUMAN
GENETICS TEAM.
    * SUBMISSION OF A CLINICAL TRIAL APPLICATION IS ESTIMATED TO
Q1
2022, AND START OF PHASE I STUDY IS ESTIMATED TO Q2 2022

Source text for Eikon:  ID:nBQN3p9nXS 
Further company coverage:  LPGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))